



## Clinical trial results:

### An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)

#### Summary

EudraCT number	2016-003403-66
Trial protocol	NL ES PT GB FR DK BE AT CZ GR SE NO FI IT
Global end of trial date	25 January 2023

#### Results information

Result version number	v1 (current)
This version publication date	09 February 2024
First version publication date	09 February 2024

#### Trial information

##### Trial identification

Sponsor protocol code	1199-0225
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03313180
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Boehringer Ingelheim
Sponsor organisation address	Binger Strasse 173, Ingelheim am Rhein, Germany, 55216
Public contact	Boehringer Ingelheim, Call Center, <a href="mailto:clintriage.rdg@boehringer-ingelheim.com">Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com</a>
Scientific contact	Boehringer Ingelheim, Call Center, <a href="mailto:clintriage.rdg@boehringer-ingelheim.com">Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com</a>

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 March 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 January 2023
Global end of trial reached?	Yes
Global end of trial date	25 January 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this trial was to assess the long-term safety of nintedanib treatment in patients with SSc-ILD.

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all subjects as required.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 December 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Brazil: 4
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Chile: 4
Country: Number of subjects enrolled	China: 17
Country: Number of subjects enrolled	Czechia: 1
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	Finland: 2
Country: Number of subjects enrolled	France: 38
Country: Number of subjects enrolled	Germany: 41
Country: Number of subjects enrolled	Greece: 7
Country: Number of subjects enrolled	India: 21
Country: Number of subjects enrolled	Israel: 7
Country: Number of subjects enrolled	Italy: 14
Country: Number of subjects enrolled	Japan: 53
Country: Number of subjects enrolled	Malaysia: 4

Country: Number of subjects enrolled	Mexico: 1
Country: Number of subjects enrolled	Netherlands: 14
Country: Number of subjects enrolled	Norway: 4
Country: Number of subjects enrolled	Poland: 14
Country: Number of subjects enrolled	Portugal: 10
Country: Number of subjects enrolled	Spain: 24
Country: Number of subjects enrolled	Sweden: 1
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	Thailand: 4
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	United States: 106
Worldwide total number of subjects	444
EEA total number of subjects	192

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	341
From 65 to 84 years	103
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This was a prospective, open-label extension trial to assess long-term safety and tolerability of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who had completed treatment of the randomised, double-blind, placebo-controlled parent trial 1199.214 or trial 1199-0340.

### Pre-assignment

Screening details:

Only patients with SSc-ILD who completed one of the parent trials on treatment (i.e., did not discontinue treatment early) were eligible and were included in this trial if they fulfilled all the inclusion criteria and did not present any of the exclusion criteria.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

This was an open-label extension trial and treatment allocation was not concealed throughout the trial.

### Arms

Arm title	Nintedanib
-----------	------------

Arm description:

Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial. Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator.

Arm type	Experimental
Investigational medicinal product name	Nintedanib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (nintedanib or placebo) in the parent trial.

Number of subjects in period 1	Nintedanib
Started	444
Completed	265
Not completed	179
Adverse event, serious fatal	20
Consent withdrawn by subject	39
Adverse event, non-fatal	100
Covid-19 related	2

Other than listed above	15
Lost to follow-up	3

## Baseline characteristics

### Reporting groups

Reporting group title	Nintedanib
Reporting group description:	
Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial. Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator.	

Reporting group values	Nintedanib	Total	
Number of subjects	444	444	
Age categorical			
Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	341	341	
From 65-84 years	103	103	
85 years and over	0	0	
Age Continuous			
Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication			
Units: years			
arithmetic mean	55.0		
standard deviation	± 11.9	-	
Sex: Female, Male			
Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication			
Units: Participants			
Female	335	335	
Male	109	109	
Race (NIH/OMB)			
Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication			
Units: Subjects			
American Indian or Alaska Native	4	4	
Asian	110	110	
Native Hawaiian or Other Pacific Islander	2	2	
Black or African American	18	18	
White	308	308	
More than one race	2	2	
Unknown or Not Reported	0	0	

Ethnicity (NIH/OMB)			
Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication			
Units: Subjects			
Hispanic or Latino	38	38	
Not Hispanic or Latino	406	406	
Unknown or Not Reported	0	0	

## End points

### End points reporting groups

Reporting group title	Nintedanib
Reporting group description: Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial. Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator.	

### Primary: Number of patients with any adverse event (AE) over the course of the trial

End point title	Number of patients with any adverse event (AE) over the course of the trial <sup>[1]</sup>
-----------------	--

End point description:

Number of patients with any adverse event (AE) over the course of the trial.

Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication

End point type	Primary
----------------	---------

End point timeframe:

First trial medication intake up to last trial drug intake, plus 7 days residual effect period, up to approximate 60 months.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Results were analyzed descriptively, no statistical analyses was planned for this endpoint.

<b>End point values</b>	Nintedanib			
Subject group type	Reporting group			
Number of subjects analysed	444			
Units: Participants	441			

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

First trial medication intake up to last trial drug intake, plus 7 days residual effect period, up to ~59.9 months.

Adverse event reporting additional description:

Treated Set (TS): all patients who signed informed consent and received at least 1 dose of trial medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	Nintedanib
-----------------------	------------

Reporting group description:

Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (nintedanib or placebo) in the parent trial.

patients receiving 100 mg bid trial medication at the end of the parent trial could receive either nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator.

Serious adverse events	Nintedanib		
Total subjects affected by serious adverse events			
subjects affected / exposed	198 / 444 (44.59%)		
number of deaths (all causes)	23		
number of deaths resulting from adverse events	19		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bowen's disease			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Acute myeloid leukaemia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenoid cystic carcinoma			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Angiomyolipoma				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Basal cell carcinoma				
subjects affected / exposed	4 / 444 (0.90%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Breast cancer				
subjects affected / exposed	3 / 444 (0.68%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Tongue neoplasm malignant stage unspecified				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lung adenocarcinoma				
subjects affected / exposed	3 / 444 (0.68%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Lung neoplasm malignant				
subjects affected / exposed	5 / 444 (1.13%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Meningioma				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metastases to bone				

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases to gallbladder			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases to liver			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases to lymph nodes			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Papillary thyroid cancer			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Parathyroid tumour benign			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer metastatic			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Splenic marginal zone lymphoma			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of skin			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
T-cell type acute leukaemia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Colon cancer			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Raynaud's phenomenon			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Arteriosclerosis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Dry gangrene			

subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Extremity necrosis			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peripheral artery occlusion			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Chest discomfort			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Disease progression			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General physical health deterioration			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polyserositis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anti-neutrophil cytoplasmic antibody positive vasculitis			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			

Heavy menstrual bleeding			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ovarian cyst			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute pulmonary oedema			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Cough			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	13 / 444 (2.93%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 2		

Paranasal sinus discomfort				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleurisy				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleuritic pain				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pneumomediastinum				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	3 / 444 (0.68%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 1			
Pneumothorax spontaneous				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary arterial hypertension				
subjects affected / exposed	9 / 444 (2.03%)			
occurrences causally related to treatment / all	0 / 9			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				



subjects affected / exposed	8 / 444 (1.80%)		
occurrences causally related to treatment / all	4 / 8		
deaths causally related to treatment / all	0 / 0		
Pulmonary fibrosis			
subjects affected / exposed	7 / 444 (1.58%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Pulmonary hypertension			
subjects affected / exposed	17 / 444 (3.83%)		
occurrences causally related to treatment / all	2 / 18		
deaths causally related to treatment / all	0 / 2		
Pulmonary mass			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	5 / 444 (1.13%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 1		
Sleep apnoea syndrome			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tracheal stenosis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	9 / 444 (2.03%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	4 / 444 (0.90%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Ejection fraction decreased			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatic enzyme increased			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Human metapneumovirus test positive			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Weight decreased			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural			

complications				
Fall				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Animal bite				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dislocation of vertebra				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rib fracture				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Spinal compression fracture				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Spleen contusion				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sternal fracture				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Thoracic vertebral fracture				

subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Upper limb fracture			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	7 / 444 (1.58%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 2		
Cardiac arrest			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Acute left ventricular failure			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Angina unstable			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arrhythmia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Arteriosclerosis coronary artery			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	5 / 444 (1.13%)		
occurrences causally related to treatment / all	1 / 5		
deaths causally related to treatment / all	0 / 0		
Atrial flutter			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Atrial tachycardia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac failure chronic			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chordae tendinae rupture			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Palpitations			

subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mitral valve incompetence			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Left ventricular failure			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Coronary artery occlusion			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Right ventricular failure			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Carpal tunnel syndrome			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral infarction			

subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Cerebral ischaemia				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Epilepsy				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hypoaesthesia				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Intracranial mass				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Paraesthesia				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sciatica				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Transient ischaemic attack				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Cerebral haematoma				

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Anaemia of chronic disease</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Autoimmune haemolytic anaemia</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Lymphadenopathy</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Ear and labyrinth disorders</b>			
<b>Sudden hearing loss</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Eye disorders</b>			
<b>Blindness unilateral</b>			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cataract</b>			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		



Glaucoma			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Retinal detachment			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Retinal tear			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vitreous detachment			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal pseudo-obstruction			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enterocolitis			

subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Enteritis				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Dysphagia				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diarrhoea haemorrhagic				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	4 / 444 (0.90%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 0			
Colitis ulcerative				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	3 / 444 (0.68%)			
occurrences causally related to treatment / all	2 / 3			
deaths causally related to treatment / all	0 / 0			
Upper gastrointestinal haemorrhage				

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal prolapse			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumoperitoneum			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumatosis intestinalis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Liver injury			
subjects affected / exposed	5 / 444 (1.13%)		
occurrences causally related to treatment / all	4 / 5		
deaths causally related to treatment / all	0 / 0		
Hydrocholecystis			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic function abnormal			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Drug-induced liver injury			
subjects affected / exposed	4 / 444 (0.90%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Ischaemic skin ulcer			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sclerema			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin hypertrophy			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin lesion			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin necrosis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin ulcer			
subjects affected / exposed	8 / 444 (1.80%)		
occurrences causally related to treatment / all	0 / 15		
deaths causally related to treatment / all	0 / 0		
Scleroderma associated digital ulcer			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	4 / 444 (0.90%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Glomerulonephritis rapidly progressive			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Musculoskeletal and connective tissue disorders			
Cervical spinal stenosis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Connective tissue disorder			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Crowned dens syndrome			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myopathy			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis of jaw			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polymyalgia rheumatica			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Scleroderma			
subjects affected / exposed	4 / 444 (0.90%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		

Sjogren's syndrome			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Systemic scleroderma			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Trismus			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthritis bacterial			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemophilus infection			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infected bunion			

subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infected skin ulcer				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Labyrinthitis				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Localised infection				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Bronchitis viral				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
COVID-19				



subjects affected / exposed	9 / 444 (2.03%)			
occurrences causally related to treatment / all	0 / 10			
deaths causally related to treatment / all	0 / 1			
COVID-19 pneumonia				
subjects affected / exposed	3 / 444 (0.68%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Clostridium colitis				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Device related infection				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Diarrhoea infectious				
subjects affected / exposed	2 / 444 (0.45%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Enteritis infectious				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Escherichia infection				
subjects affected / exposed	1 / 444 (0.23%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gallbladder abscess				

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pharyngotonsillitis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	26 / 444 (5.86%)		
occurrences causally related to treatment / all	1 / 30		
deaths causally related to treatment / all	0 / 0		
Pneumonia aspiration			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonia bacterial			
subjects affected / exposed	3 / 444 (0.68%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia viral			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Propionibacterium infection			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Staphylococcal infection			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Subperiosteal abscess			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Tooth abscess			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	4 / 444 (0.90%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Cachexia			

subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Decreased appetite			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypocalcaemia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	2 / 444 (0.45%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Hypomagnesaemia			
subjects affected / exposed	1 / 444 (0.23%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Nintedanib		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	425 / 444 (95.72%)		
Vascular disorders			
Raynaud's phenomenon			
subjects affected / exposed	18 / 444 (4.05%)		
occurrences (all)	19		
Hypertension			
subjects affected / exposed	23 / 444 (5.18%)		
occurrences (all)	27		
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	22 / 444 (4.95%)		
occurrences (all)	29		
Fatigue			
subjects affected / exposed	46 / 444 (10.36%)		
occurrences (all)	55		
Pyrexia			
subjects affected / exposed	28 / 444 (6.31%)		
occurrences (all)	35		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	83 / 444 (18.69%)		
occurrences (all)	106		
Dyspnoea			
subjects affected / exposed	47 / 444 (10.59%)		
occurrences (all)	57		
Oropharyngeal pain			
subjects affected / exposed	18 / 444 (4.05%)		
occurrences (all)	22		
Productive cough			
subjects affected / exposed	16 / 444 (3.60%)		
occurrences (all)	16		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	14 / 444 (3.15%)		
occurrences (all)	17		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	47 / 444 (10.59%)		
occurrences (all)	73		
Aspartate aminotransferase increased			
subjects affected / exposed	43 / 444 (9.68%)		
occurrences (all)	61		
Gamma-glutamyltransferase increased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>33 / 444 (7.43%)</p> <p>45</p> <p>63 / 444 (14.19%)</p> <p>81</p>		
<p>Injury, poisoning and procedural complications</p> <p>Fall</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Limb injury</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>16 / 444 (3.60%)</p> <p>18</p> <p>22 / 444 (4.95%)</p> <p>25</p>		
<p>Nervous system disorders</p> <p>Dizziness</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>24 / 444 (5.41%)</p> <p>30</p> <p>55 / 444 (12.39%)</p> <p>80</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>24 / 444 (5.41%)</p> <p>28</p>		
<p>Gastrointestinal disorders</p> <p>Dysphagia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspepsia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>21 / 444 (4.73%)</p> <p>23</p> <p>20 / 444 (4.50%)</p> <p>25</p> <p>338 / 444 (76.13%)</p> <p>1100</p> <p>20 / 444 (4.50%)</p> <p>27</p>		

Abdominal pain upper subjects affected / exposed occurrences (all)	24 / 444 (5.41%) 37		
Abdominal pain subjects affected / exposed occurrences (all)	52 / 444 (11.71%) 85		
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	43 / 444 (9.68%) 50		
Nausea subjects affected / exposed occurrences (all)	122 / 444 (27.48%) 168		
Vomiting subjects affected / exposed occurrences (all)	100 / 444 (22.52%) 161		
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	20 / 444 (4.50%) 27		
Skin ulcer subjects affected / exposed occurrences (all)	110 / 444 (24.77%) 261		
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	75 / 444 (16.89%) 106		
Back pain subjects affected / exposed occurrences (all)	41 / 444 (9.23%) 43		
Pain in extremity subjects affected / exposed occurrences (all)	31 / 444 (6.98%) 39		
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	46 / 444 (10.36%) 69		

Urinary tract infection			
subjects affected / exposed	43 / 444 (9.68%)		
occurrences (all)	80		
Upper respiratory tract infection			
subjects affected / exposed	76 / 444 (17.12%)		
occurrences (all)	116		
Respiratory tract infection			
subjects affected / exposed	27 / 444 (6.08%)		
occurrences (all)	41		
Nasopharyngitis			
subjects affected / exposed	82 / 444 (18.47%)		
occurrences (all)	130		
Influenza			
subjects affected / exposed	23 / 444 (5.18%)		
occurrences (all)	23		
Herpes zoster			
subjects affected / exposed	19 / 444 (4.28%)		
occurrences (all)	21		
COVID-19			
subjects affected / exposed	68 / 444 (15.32%)		
occurrences (all)	80		
Viral infection			
subjects affected / exposed	17 / 444 (3.83%)		
occurrences (all)	30		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	33 / 444 (7.43%)		
occurrences (all)	36		
Hypokalaemia			
subjects affected / exposed	21 / 444 (4.73%)		
occurrences (all)	29		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 August 2017	The changes to the CTP included clarifications and corrections to the schedule of assessments, the frequency of Thyroid-stimulating hormone (TSH) testing, the creatinine clearance measurement formula, and procedures to be followed in case of pregnancy in a trial patient or their partner.
17 August 2018	<p>The following main changes, clarifications, and corrections of inconsistencies were implemented:</p> <ul style="list-style-type: none"><li>. Patients who completed trial 1199-0340 (approximately 14 patients) were added to the pool of patients who could enter the present trial</li><li>. Selexipag was added to the list of oral or parenteral therapies for pulmonary hypertension; patients treated for pulmonary hypertension were highly recommended to discontinue nintedanib in Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS-ON)</li><li>. Clarification of the collected blood volume for safety laboratory tests (110 (milliliter) mL in the first year and 45 mL during any subsequent year)</li><li>. An inconsistency in the list of procedures to be done at dose-modification visits was corrected to include safety laboratory testing</li><li>. The length of the Residual Effect Period (REP) was corrected from 28 days to 7 days, based on the half-life of nintedanib</li></ul>
13 August 2020	<p>The following changes, clarifications, and corrections of inconsistencies were implemented:</p> <ul style="list-style-type: none"><li>. The introduction was updated to ensure it reflected current knowledge and recent data on the medical background relevant to this trial</li><li>. The benefit-risk assessment was updated to reflect new information on the Covid-19 pandemic</li><li>. The duration of the trial design was clarified, the end of the trial was more precisely described, and it was documented that the trial could last beyond availability of marketed drug</li><li>. The numbers of wallets provided at Visits 5 and 6 were corrected</li><li>. The recommendations for cases of hepatic injury were changed:<ul style="list-style-type: none"><li>o The wording regarding withdrawal and interruption of trial medication was revised for clarification. It was also noted that trial medication could be resumed if clear evidence of an alternative cause for hepatic injury was identified. It was specified that this was only possible after consultation with the sponsor and if prior to restart, liver laboratory values were normal. Liver laboratory values had to be monitored weekly for the first 4 weeks after reintroduction and every 2 weeks for the following 8 weeks.</li></ul></li><li>. Following the first wave of the Covid-19 pandemic, the visit schedule was modified for exceptional circumstance (such as a pandemic) to allow flexibility in visit conduct to ensure patients safety by ensuring continuous treatment.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported